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Neurodegenerative diseases are intricate in nature because of the involvement
of the multiple pathophysiological events including mitochondrial dysfunction,
neuroinflammation and oxidative stress. Alzheimer’s disease (AD) is a neurodegenerative
disease explained by extracellular amyloid b deposits, intracellular neurofibrillary tangles
and mitochondrial dysfunction. Increasing evidence has indicated that mitochondrial
dysfunction displays significant role in the pathophysiological processes of AD.
Mitochondrial dysfunction involves alterations in mitochondrial respiratory enzyme
complex activities, oxidative stress, opening of permeability transition pore, and
enhanced apoptosis. Various bioenergetics and antioxidants have been tried or under
different investigational phase against AD and other neurodegenerative disorders
(Parkinson’s disease, Huntington’s disease, and Amyotrophic lateral sclerosis) because
of their complex and multiple site of action. These mitochondrial-targeting bioenergetics
and antioxidant compounds such as coenzyme Q10, idebenone, creatine, mitoQ,
mitovitE, MitoTEMPOL, latrepirdine, methylene blue, triterpenoids, SS peptides,
curcumin, Ginkgo biloba, and omega-3 polyunsaturated fatty acids with potential
efficacy in AD have been identified. Present review is intent to discuss mitochondrial
restorative mechanisms of these bioenergetics and antioxidants as a potential alternative
drug strategy for effective management of AD.
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Introduction
Alzheimer’s disease (AD) common incapacitating neurodegenerative disease, identified by the
occurrence of senile plaques extracellularly and neurofibrillary tangles intracellularly (Alzheimer’s,
2015; Kumar et al., 2015). Globally AD is becoming epidemic because of new cases in every 7 s
and more than 36.5 million individuals are affected worldwide (Prince et al., 2014; Alzheimer’s,
2015). Senile plaque consists of amyloid b (Ab) peptides and tangles are made from tau protein.
It was found that Ab peptides are produced by the proteolytic segmentation of the protein known
as amyloid precursor protein (APP). Other characteristic features of AD include progressive and
neuronal synaptic loss, mitochondrial dysfunction, oxidative stress and inflammatory responses
(Iqbal and Grundke-Iqbal, 2010; Swerdlow et al., 2014; Alzheimer’s, 2015). An increasing body of
evidences indicates that Ab enhances neuronal vulnerability to mitochondrial dysfunction via an
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impairment of electron transport chain (ETC) and oxidative stress
(Davis et al., 1995; Reddy and Beal, 2008; Reddy et al., 2010;
Calkins et al., 2011; Swerdlow et al., 2014).
Till date, rigorous efforts have been made to understand
the complex pathophysiological mechanisms’ underlying AD
and other neurodegenerative disorders including Parkinson’s
disease (PD), Huntington’s disease (HD), and Amyotrophic
lateral sclerosis (ALS) but still it remains ill-defined and poorly
understood disease. There have been many hypotheses put
forward to explain their complex pathophysiology such as
inflammatory, mitochondrial dysfunction and oxidative stress
hypotheses (Kumar and Singh, 2015). Out of these hypotheses,
mitochondrial dysfunction and oxidative stress hypotheses are
the most argued one (Davis et al., 1995; Swerdlow et al.,
2014). As these two events are occurring at very early stages
of neurodegenerative diseases so these can be one of the
important and potential therapeutic targets in the current scenario
(Swerdlow et al., 2014).
Mitochondria, the major organelles in neurons (Chaturvedi
and Beal, 2013) and via oxidative phosphorylation (OXPHOS)
or mitochondrial respiratory chain produce energy as adenosine
triphosphate (ATP; Schapira, 2012; Zeviani et al., 2012).
Other functions of mitochondria are the regulation of calcium
homeostasis, generation of free radicals and apoptosis (Swerdlow,
2011). Strong evidence indicated that mitochondrial dysfunction
involves alterations of mitochondrial respiratory chain enzymes,
generation of reactive oxygen species (ROS), opening of
mitochondrial permeability transition pore (mPTP), structural
abnormalities of mitochondria, oxidative stress and apoptosis
(Hauptmann et al., 2006; Lin and Beal, 2006; Eckert and Müller,
2014). And these mitochondrial abnormalities are known to
occur early in AD before Ab deposition and are closely related
to Ab- or tau- pathology (Swerdlow et al., 2010; Maruszak and
Żekanowski, 2011).
Various compounds have been demonstrated to possess
mitochondrial restoring and anti-oxidant properties such as
coenzyme Q10 (CoQ 10), vitamin E, curcumin, Gingko biloba,
melatonin and lipoic acid (Du and Yan, 2010). Therapeutic
potentials of these compounds have been suggested to reduce
Ab peptides accumulations, restoring mitochondrial functions,
transport and synaptic plasticity, protect mitochondria from
Ab toxicity, attenuate cognitive impairment in AD, inhibit
dopaminergic neuronal loss in PD and showed neuroprotective
role in other neurodegenerative disorders like ALS, HD
(Hauptmann et al., 2006; Lin and Beal, 2006; Pieczenik and
Neustadt, 2007; Moreira et al., 2010; Maruszak and Żekanowski,
2011).
One of the important tasks of this review is to discuss
the growing evidences demonstrating the importance of
mitochondria and related features in the pathogenesis of AD.
Finally, we will discuss mitochondrial dysfunction as a potential
drug target for AD management. The authors also projected
various drug strategies targeting mitochondrial dysfunction and
oxidative stress which may help in attenuation of AD, PD, HD,
and ALS pathologies. Also, an attempt has been made to discuss
various compounds targeting mitochondria and oxidative stress
as a future approach with major focus on AD pathology.
Mitochondrial Cascade Hypothesis
As discussed earlier, that the pathology of AD involves the
extracellular aggregation of Ab plaques and intracellular
neurofibrillary tangles (Kumar and Singh, 2015). It was first
suggested by Swerdlow in 2004 (Swerdlow and Khan, 2004)
and according to this hypothesis; mitochondrial dysfunction
is considered to be an early as well as a primary event in the
pathophysiological cascade of AD (Swerdlow et al., 2010). Also
it was proposed that genetic hereditary regulate mitochondrial
functions and membrane strength, which changes with age
and hence results in the development of AD related symptoms
(Swerdlow and Khan, 2004; Swerdlow et al., 2010). This
hypothesis assumed that autosomal dominant and sporadic AD
are not etiologically same (Swerdlow et al., 2014). Mitochondrial
dysfunction presents a connecting link between sporadic AD
and autosomal dominant. In autosomal dominant AD, excessive
Ab accumulation slowly impairs mitochondrial functions which
further initiate other AD related pathologies such as oxidative
stress or neuroinflammation. In sporadic AD, age related
occurrence of mitochondrial dysfunctions causes a variety of
pathologies including oxidative stress and apoptosis (Hauptmann
et al., 2006; Lin and Beal, 2006; Moreira et al., 2010; Witte et al.,
2010).
Mechanism of Mitochondrial Dysfunction
in AD
As reported earlier, in AD there is abnormal APPmetabolism and
an excessive Ab accumulation (Kumar and Singh, 2015). It has
been reported that Ab peptides are present in the neuronal cells
as well as in mitochondria (Swerdlow and Khan, 2004). When
Ab peptides accumulates in mitochondria it causes inhibition
of mitochondrial respiratory enzyme complex-II and IV, causes
decreased production of ATP and an increased production of
ROS mitochondrial dysfunction in AD (Figure 1, Rhein et al.,
2009; Swerdlow et al., 2010). Accumulation of Ab peptides
also known to reduce activity of enzyme of the tricarboxylic
acid (TCA) cycle, a-ketoglutarate dehydrogenase (aKGD),
pyruvate dehydrogenase and isocitrate dehydrogenase (Huang
et al., 2003; Bubber et al., 2005). It is reported that, Ab peptides
interact with the Ab binding site known as Ab binding alcohol
dehydrogenase (ABAD) which are present in the mitochondrial
membranes and causes mitochondrial dysfunction (Lustbader
et al., 2004), abnormal mitochondrial trafficking and decreased
mitochondrial movement finally leads to synaptic degeneration
(Calkins and Reddy, 2011). Further, Ab peptide accumulation
leads to dysfunctioning of mitochondrial Ca2+ channels, opening
of mPTP and enhancement of cytochrome C (CytC) release
(Calkins et al., 2011). Moreover, Ab peptide accumulation
inhibits protein import inside the mitochondria, which leads
to mutation of mitochondrial DNA (mtDNA) and its damage
(Lakatos et al., 2010). Mutations in APP also cause alterations
of Ca2+ homeostasis leading to apoptosis (Khan et al., 2000).
Accumulation of Ab peptide and hyperphosphorylation of tau
causes increased DRP-1nitrosylation which in turn causes abrupt
mitochondrial fission and neurodegeneration (Manczak et al.,
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FIGURE 1 | Mechanism of mitochondrial dysfunction in Alzheimer’s disease. (Ab-amyloid b, OXPHOS- oxidative phosphorylation, ROS- reative oxygen
species, mPTP- mitochondrial permeability transition pore, Cyt C- cytochrome C, Drp1- dynamin—related protein-1, ABAD- amyloid b binding alcohol
dehydrogenase, a-KGDH- a-ketoglutarate dehydrogenase complex, PGC-1a- peroxisome proliferator activated receptor-g-coactivator-1-a). Adopted and modified
from Reddy and Beal (2008).
2011). Accumulation of soluble Ab peptide and mutant APP
impairs mitochondrial fusion and fission functions, abnormal
mitochondrial movement, morphology and degradation of
mitochondria (Manczak et al., 2011). Besides, it has also
been reported that Ab peptide accumulation causes abnormal
expression of mitochondrial fission (Fis1) and fusion (mfn1/2
and OPA1) proteins which are involved in mitochondrial
fission and fusion machinery (Manczak et al., 2011). These
impaired dynamics causes decreased clearance of defective
mitochondria which further enhanced neurodegeneration
(Manczak et al., 2011). It has been studied that Ab peptides
induced hyperphosphorylation of tau causes inhibition of
fission protein DRP1 which leads to abnormal mitochondrial
elongation (Wang et al., 2008). In another study, Ab peptides
decrease proliferator-activated receptor-g coactivator-1 a
(PGC-1a) expressions, which leads to decreased mitochondrial
biogenesis, mitochondrial DNA content (mtDNA) and increased
neurodegeneration (McGill and Beal, 2006). Activation of
PGC-1a causes increased non-amyloidogenic processing of APP,
reduction in Ab levels leading to increased survival of neuronal
cells (McGill and Beal, 2006).
Mitochondria in AD
Mitochondria are the major energy producing cell organelles
and also known as the power house of the cell (Du and Yan,
2010). Studies have expanded the role of the mitochondrial
genome, consisting of maternally-inherited multiple copies of
semi-autonomous genome mtDNA along with thousands of
nuclear DNA (nDNA)-encoded genes (Castellani et al., 2002;
Selfridge et al., 2013). The mtDNA encodes major components
of mitochondrial OXPHOS which includes specifically ETC
(Castellani et al., 2002). On the other side, nDNA encodes the
genes which are required for the assembly of mitochondria and its
related structural elements (Castellani et al., 2002; Selfridge et al.,
2013). Therefore, mitochondrial respiratory rate, oxidative stress
and apoptosis, which constitute important byproduct of OXPHOS
(Selfridge et al., 2013).
In 1995, Jane C. Chisholm and his team proposed
“mitochondrial bottle neck hypothesis.” According to this
hypothesis, mitochondria represent a unique target for
therapeutic interventions for all forms of AD (Davis et al., 1995).
Besides, mitochondrial functions are essential as well as their
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FIGURE 2 | Role of mitochondria in AD. In early-onset AD, it is hypothesized that mitochondria leads to the generation of free radicals (O2
—, H2O2), which in turn
decrease cytochrome oxidase activity and inhibit cellular ATP generation. Further in late-onset AD, free generation actives BACE mediated cleavage of Ab. Again Ab
enter into the mitochondria and induces free radicals that leads to disruptions of ETC, decrease in cytochrome oxidase activity and the inhibition of ATP which finally
leads to neuronal damage and cognitive decline in AD.
dysfunction are sufficient enough to cause neurodegenerative
disorder, including AD and thus providing mechanistic
bottleneck in neurodegenerative diseases. In AD, multiple
heterogeneous natures cause the same pathological phenotype in
mitochondria. This hypothesis also proposed that mitochondrial
dysfunction is a common pathway in different neurodegenerative
disorders (Davis et al., 1995).
It has been reported that several mitochondrial respiratory
enzymes (pyruvate dehydrogenase complex, ketoglutarate
dehydrogenase complex, and cytochrome oxidase) are altered
in AD (Moreira et al., 2010). According to the mitochondrial
cascade hypothesis, defect in cytochrome oxidase is considered
to be central. Cytochrome oxidase is the major enzymes of the
terminal end of mitochondrial ETC. It accepts electron from
cytochrome c, which in turn receive it from the upstream part of
ETC. Cytochrome oxidase transfer electron to oxygen to form
H2O rather than ROS. And this enzyme is the common site for
all cellular oxygen consumption (Swerdlow et al., 2014).
It is well documented that reduced cytochrome oxidase activity
is correlated with an increased defects in mtDNA in AD
(Swerdlow et al., 2014). The brain, due to the presence of high
lipid content, high oxygen consumption and low antioxidant
defenses, remains the most vulnerable organ to oxidative stress.
It is also well documented that free radical generation by
mitochondrial dysfunction affect both in neurons and astrocytes
during AD. There is also generation of free radicals (O2—)
produced in mitochondrial ETC complexes I and III and enzymes
of the TCA (a-ketoglutarate dehydrogenase) in AD. From
inner mitochondrial membranes hydrogen peroxide (H2O2) and
O2— is released to the outer side (cytoplasm) which finally
causes oxidation of cytoplasmic proteins (Figure 2; Ylikallio and
Suomalainen, 2012). Figure 2 has been adopted and the modified
from Reddy and Beal (2008).
Various studies have been performed to understand the
relationship between Ab and mitochondria (Rhein et al., 2009;
Ren et al., 2011). Study in transgenic mice (tgAPP/PS1) has
shown that the soluble form of Ab peptide causes a reduced
mitochondrial membrane potential (MMP) and ATP levels (Ren
et al., 2011). Another study on triple transgenic (APP/TAU/PS2)
AD mice showed that decreased mitochondrial protein levels
include reduction of the MMP and ATP synthesis (Rhein et al.,
2009). In vivo study showed that intrahippocampal injection of
Ab peptides damaged mitochondria, causes a decreased Ca2+
dependent ATPase activity, MMP and an increased Ca2+ levels
(Calkins et al., 2011). It has also been reported the correlation
between Ab and tau, it is described that both Ab and tau
work synergistically and leads to the impairment of oxidative
phosphorylation (Rhein et al., 2009). Due to the accumulation
of Ab peptides in the mitochondrial import channels (TIM23
and TOM40) and mutant APP in AD brain causes mitochondrial
dysfunction (Devi et al., 2006). A study on transgenic mice
showed that APP (full length segment) binds to the mitochondria
in neuronal cells, causes impaired energy metabolism and
mitochondrial dysfunction (Anandatheerthavarada et al., 2003).
It has been observed that during AD there is decreased
genetic expression of oxidative phosphorylation and energy
consumption (Chandrasekaran et al., 1996). A study on triple
transgenic mouse (APP/PS1/Tau) showed dysregulated oxidative
phosphorylation, glycolysis, TCA cycle, pyruvate metabolism,
and mitochondrial protein synthetic pathways by the help of
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FIGURE 3 | Various drugs and natural compounds with common
potential therapeutic target mitochondria in Alzheimer’s disease.
mitochondrial proteome analysis (Chou et al., 2011). Similarly, a
study in Ab transgenic mouse model of AD showed an impaired
mitochondrial functions, ROS production,MMP and cytochrome
c oxidase (COX) activity (Dragicevic et al., 2010).
Mitochondrial Therapeutics in
Neurodegenerative Diseases
As previously discussed, alteration in mitochondrial bioenergetic
defects, mitochondrial dynamics and mitochondrial trafficking
and oxidative stress ROS mediated mitochondria damage plays
a key role in AD, PD, HD, and ALS pathogenesis (Reddy
and Beal, 2008; Chaturvedi and Beal, 2013). So, strategies that
target mitochondrial dysfunction or the agents which enhance
mitochondrial bioenergetics and reversed oxidative stress are
potentially needed as therapeutics in AD, PD, HD, and ALS. Here
we discussed the therapeutic potential of various bioenergetics
and antioxidants (Figure 3) which are either have been used or
being in different phases of clinical trials.
Coenzyme Q 10
Mechanism of Action
It is an important cofactor of the ETC, known as ubiquinone.
It functions as an electron acceptor for complex I and II and
also act as an antioxidant in mitochondria and its membranes
(Hargreaves, 2014). It is present in the inner mitochondrial
membrane as a cofactor for three mitochondrial complexes
(complexes I, II, and III) which play major role in OXPHOS
(Hargreaves, 2014). According to Muller, one of the major
functions of CoQ10, non-protein component of ETC, is to move
and transfer electrons between flavoproteins and cytochromes
(Müller et al., 2003). Further, it has been proposed that
electrons of ETC must first be interact with CoQ10, a central
rate-limiting step, hence considered as major component of
ETC (Cleren et al., 2008). The major role of CoQ10 is ATP
production. It also possesses antiapoptotic activity by inhibiting
activation of the mitochondrial permeability independent of
its free radical scavenging property (Matthews et al., 1998).
It also acts as a cofactor as well as obligatory cofactor of
mitochondrial uncoupling proteins whose activation reduces free
radical generation frommitochondrial (Beal andMatthews, 1997;
Kašparová et al., 2006).
Preclinical Studies
In vitro and in vivo analysis have suggested the neuroprotective
potentials of CoQ10 in AD (Ishrat et al., 2006; Choi et al.,
2012). It is a lipophilic anti-oxidant compound that improves
cognitive functions, facilitates ATP synthesis and up-regulates
mitochondrial function (Turunen et al., 2004). It is well
documented that CoQ10 supplementation significantly
increases endogenous brain CoQ10 content and provides
protection from free radicals mediated oxidative damage
biomolecules (Hargreaves, 2014). It also acts as cofactor of
dehydrogenase in the ATP production and electrons and
proton transport. Previous study on primary neuron culture
suggests that CoQ10 significantly inhibit chemically (like
paraquat and rotenone) induced mitochondrial dysfunction,
maintained MMP, inhibit the mitochondrial ROS generation
and neurodegeneration (Chaturvedi and Beal, 2008). CoQ10
also protects cultured cerebellar neurons against excitotoxin
induced degeneration. A study on ICV-STZ infused rat showed
that CoQ10 supplementation significantly restored choline acetyl
transferase activity (Ishrat et al., 2006).
Clinical Studies
It is further evident from clinical studies that high doses of CoQ10
are beneficial for the treatment of neurodegenerative diseases
(Crane, 2007; Galpern and Cudkowicz, 2007; Lenaz et al., 2007).
Clinical study for the evaluation of safety and tolerability of
CoQ10 and its combination treatment of mild to moderate AD
patients (NCT00117403) is currently in ongoing phase (Müller
et al., 2003). In this study, seventy five subjects received CoQ10
2400 mg daily; vitamin E 2400 IU, vitamin C 600 mg and a-
lipoic acid 1800 mg; or placebo for a period of 4 months. Various
parameters like safety, tolerability, CSF biomarkers of oxidative
stress as well as CSF concentration of Ab (1–40) and (1–42) were
evaluated (Müller et al., 2003). Another study, phase-I pilot trial,
an open label trial in 15 PD patients, was conducted for the
safety and CoQ10 tolerability (Shults et al., 1998). In this study,
CoQ10 at different doses 400, 600, and 800 mg/day for a period
of 1 month showed significant safety and tolerability profiles
along with dose-dependent increase in plasma CoQ10 levels
(Shults et al., 1998). Another clinical trial (open label placebo
controlled) in ALS patients showed that COQ10 (3000 mg/day)
is safe and well tolerated (Ferrante et al., 2005). Recent clinical
trial (multicenter, two-stage) in Phase II on CoQ10 showed no
significant results between CoQ10 and placebo (Kaufmann et al.,
2009).
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Creatine
Mechanism of Action
Creatine, a nitrogenous guanidino compound, provides energy to
the nerve and muscle cells due to its high energy requirement
(Beal, 2011). It is a potent antioxidant and acts as an effective
mPTP opening inhibitor and mitochondrial iron accumulation
(Beal, 2011). It is present in the form of free creatine and
phosphocreatine (PCr) in the human body. It is further gets
transformed into PCr by the help of creatine kinase (CK) in
skeletal muscle and brain. CK maintains cellular homeostasis by
creating a pool of PCr for ATP generation (Adhihetty and Beal,
2008).
Preclinical Studies
It exert neuroprotective potential in different neurodegenerative
disorders like AD, PD, HD, and ALS (Adhihetty and Beal, 2008;
Beal, 2011). In vitro studies on neuronal cells have shown that
it protects against neurotoxicity induced by 3-nitropropionic
acid (3-NP), 1-methyl-4-phenylpyridinium (MPP+), and 6-
hydroxydopamine (6-OHDA), glucose and serum deprivation
(Chaturvedi and Beal, 2008). Creatine administration also
known to inhibit the degeneration of dopaminergic neurons and
reduced depletion of dopamine levels in PD (Matthews et al.,
1999). Besides, creatine supplementation has been proved to be
effective and protective against neuronal death caused by NMDA,
malonate, Ab and ibotenic acid induced neurotoxic injuries
(Chaturvedi and Beal, 2008). Study on transgenic G93A ALS
mice showed that creatine treatment protects motor neurons,
brain atrophy and reduced mitochondrial dysfunction (Klivenyi
et al., 1999). Besides, creatine in combination with the other
bioenergetics compound CoQ10 produces a neuroprotective
effects in neurodegenerative diseases (Yang et al., 2009b).
Taken together, these studies may suggest creatine, a promising
therapeutic agent for various neurodegenerative disorders
including AD.
Clinical Studies
A clinical study (randomized, double-blind) of creatine in patients
with mitochondrial cytopathies, showed constructive effects of
creatine (Rodriguez et al., 2007). Another pilot study using
creatine treatment showed advantageous effects on the mood
swings of PD patients (Bender et al., 2006). In this study
creatine (4 g/day) was safe and well tolerated in aged PD
patients (Bender et al., 2008). A clinical study (randomized,
double-blind) in phase II, on HD patients, showed that creatine
(8 g/day) for 16 weeks was found to be safe and well tolerated,
and decreased serum 8-hydroxy-2-deoxyguanosine which is the
neuropathological marker for oxidative stress (Hersch et al.,
2006). Taken together, these clinical studies may suggest a
promising, beneficial and neuroprotective role of creatine in
neurodegenerative diseases.
Idebenone
Mechanism of Action
It is an analog of CoQ10 consists of short chains of isoprene
units, also known as ubiquinone. It has been reported that
Idebenone crosses blood brain barrier easily and is well tolerated
in humans (Senin et al., 1992). It is also known to possess
good anti-oxidant properties (Senin et al., 1992). It belongs
to the quinone family and is structurally similar to CoQ10
(Senin et al., 1992; Weyer et al., 1997; Gutzmann and Hadler,
1998).
Preclinical Studies
It has been reported that Idebenone produced neuroprotection
against Ab induced neurotoxicity both in vitro and in vivo (Weyer
et al., 1997).
Clinical Studies
Clinical study of Idebenone showed its neuroprotective effects in
AD patients on Alzheimer’s Disease Assessment Scale (ADAS)
score (Gutzmann and Hadler, 1998). It has been proposed that
Idebenone (360 mg/day) treatment was safe and well tolerated in
AD patients (Gutzmann et al., 2002).
Latrepirdine
Mechanism of Action
Latrepirdine previously known as Dimebon (or Dimebolin),
is a non-selective antihistamine (Sachdeva and Burns,
2011). Latrepirdine inhibits weakly acetylcholinesterase and
butyrylcholinesterase (Bachurin et al., 2001). Latrepirdine also
has known as inhibitor of NMDA receptor and voltage-gated
calcium channels. It also possesses the neuroprotective effect
mainly by maintaining mitochondrial structure and function
(Sachdeva and Burns, 2011). Latrepirdine under both stress
and non-stress conditions enhances mitochondrial function
(Bachurin et al., 2001; Sachdeva and Burns, 2011). Latrepirdine
has also been reported to inhibit Ab-induced activation of the
mPTP which can lead to apoptosis and hence protect neuronal
mitochondria from Ab-induced toxicity (Bachurin et al., 2001).
Latrepirdine other functions include an increase in MMP and
ATP production (Bachurin et al., 2001; Sachdeva and Burns,
2011).
Preclinical Studies
Latrepirdine has been shown to be effective in cognition in
animal studies on young/adult mice or rats (Kieburtz et al.,
2010; Vignisse et al., 2011). Latrepirdine also known to improve
impaired mitochondrial function in AD (Reddy, 2009; Leuner
et al., 2012). Latrepirdine (25 mmol/l) has been reported to be
protective against the Ab induced mitochondrial dysfunctions
(Reddy, 2009; Leuner et al., 2012). A study on human SH-SY5Y
neuroblastoma cells and primary rat cortical neurons showed
that latrepirdine (0.1–10 nmol/l) improvemitochondrial function,
such as MMP, ATP production and apoptosis (Zhang et al.,
2009).
Clinical Studies
Phase 2 randomized controlled trial showed that, latrepirdine
was well tolerated, safe and significantly enhanced the clinical
outcomes in patients suffering frommild-to-moderateAD (Reddy
and Reddy, 2011).
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Triterpenoids
Mechanism of Action
Triterpenoids are derivatives of oleanolic acid and known to
inhibit oxidative stress. They also possess anti-inflammatory
properties via inhibition of inflammatory processes; by activation
of antioxidant response element (ARE)-Nrf2-Keap1 signaling
pathway (Liby et al., 2005). Activation of this pathway leads
to the dissociation of Nrf2 from Keap1, translocation to the
nucleus and then binding to the ARE promoter sequences which
further causes induction of antioxidant and anti-inflammatory
genes (Yates et al., 2007). It has recently reported that synthetic
triterpenoids (CDDO) causes transcriptional activation of Nrf2,
NQO-1, HO-1, glutathione transferase and other cytoprotective
enzymes (Liby et al., 2005; Yates et al., 2007). CDDO-methyl
amide (2-cyano-N-methyl-3,12-dioxooleana-1,9 (11)-dien-28
amide; CDDO-MA), synthetic triterpenoid, has been discovered
as 200,000 times more potent inducer of NQO-1 or suppressor
of iNOS than naturally occurring oleanolic acid (Yang et al.,
2009a). Further study on same compound CDDO-MA showed
that it is a potent and selective activator of the Nrf2/ARE
pathway which is neuroprotective in nature (Kaidery et al.,
2013).
Preclinical Studies
Experimental studies on 3-NP rat model and 1-methyl-4
phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model
showed that synthetic triterpenoid CDDO-MA, exerts significant
neuroprotective effects by potently activatingNrf2/ ARE signaling
pathway (Yang et al., 2009c; Kaidery et al., 2013). CDDO-MA
has also been reported to inhibit ROS generation, MPTP induced
neurodegeneration and dopamine depletion and 3-NP induced
striatal lesions (Yang et al., 2009c). It has also been observed that
triterpenoids improve the behavioral parameters and survival in
transgenic mouse models of variety of neurodegenerative diseases
including AD, HD and ALS (Neymotin et al., 2011). These studies
may suggest that targeting neuroprotective pathways (Nrf2/ARE)
through synthetic triterpenoids (CDDO-MA) could be used as
a better therapeutic approach in the treatment and management
of neurodegenerative disorders (Dumont et al., 2009; Stack et al.,
2010).
MitoQ
Mechanism of Action
MitoQ is formed by coenzymeQ or ubiquinone which is linked to
triphosphonium ions via covalent bonding to form mitoquinone
(Murphy and Smith, 2007). It is the most widely used antioxidant
to targetmitochondria.MitoQdemonstrated neuroprotection due
to its direct effect on scavenging peroxynitrite, and superoxide,
and thus protect mitochondria against lipid peroxidation
(Manczak et al., 2010; Calkins et al., 2011; Jin et al., 2014).
Preclinical Studies
Studies on both in vitro and in vivo models showed that
it exerts neuroprotective effects in various experimental
models (Murphy and Smith, 2007; Jin et al., 2014). It also
inhibits mitochondrial fission protein and translocation of
pro-apoptotic protein (Bax) in the mitochondria in cellular
models of PD (Jin et al., 2014). Although its efficacy in
neurodegenerative diseases conditions needs to be further
explored and understood.
Clinical Studies
A clinical study (double blind), in 128 newly diagnosed untreated
patients with PD, MitoQ for 12 months with two doses did
not produce any significant improvement according to United
Parkinson Disease Rating Scale and PD progression when
compared with the placebo control (Snow et al., 2010).
MitoVitE
Mechanism of Action
MitoVitE is also known as Mito tocopherol. Structurally, it is
triphenylphosphonium (TPP) conjugated to a-tocopherol moiety
of vitamin E via two-carbon chain. It also protects mitochondria
from oxidative stress via inhibition of lipid peroxidation (Smith
et al., 1999).
Preclinical Studies
In vivo study, showed that intravenous injection of MitoVitE
accumulated rapidly in the heart, brain, muscle, liver, and kidney
tissues which are mostly affected by mitochondrial dysfunction
and oxidative stress (Smith et al., 2003). An in vitro cellular model
also demonstrated its efficacy against mitochondrial oxidative
stress, reduction of peroxide mediated oxidative stress, peroxide-
induced caspase activation and oxidative stress-induced cell death
(Jauslin et al., 2003;Dhanasekaran et al., 2004;Hughes et al., 2005).
But till date, its efficacy and therapeutic potential in PD patients
has not been investigated.
MitoTEMPOL
Mechanism of Action
It is another TPP+ derivative which consists of stable
piperidine nitroxide radical TEMPOL (4-hydroxy-2,2,6,6,-
tetramethylpiperidine- 1-oxyl). The most important property
is to accept an electron from hydroxylamine (potent radical
scavenger). It also acts as a SOD mimetic, whose function is to
converts superoxide molecules into water to detoxify ferrous iron
into ferric iron.
Preclinical Studies
In vitro study has shown its beneficial effects against
mitochondrial dysfunction and mitochondria mediated oxidative
stress (Trnka et al., 2008). However, its neuroprotective potential
in different neurological problem is yet to be explored and
understood.
SS (Szeto-Schiller) Peptides
Mechanism of Action
They are mitochondrial targeted peptides; act as novel
anti-oxidants, helpful in restoring mitochondrial functions
(Szeto, 2008). A study in isolated mitochondria showed that
these peptides decreases mitochondrial ROS generation;
inhibit mitochondrial swelling and cytochrome c release
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(Szeto, 2008; Manczak et al., 2010; Calkins et al., 2011).
Further, the modification in their structure via addition of
a tyrosine or modified tyrosine moiety causes improvement
in their free radical scavenging properties, and; apoptosis
(Manczak et al., 2010; Calkins et al., 2011; Smith and Murphy,
2011). Besides, their related peptides (SS-31 and SS-20)
have also been shown to restore mitochondrial functional
properties by reducing inhibition of the mitochondrial
ETC, apoptosis and oxidative stress (Smith and Murphy,
2011).
Preclinical Studies
A study showed that SS peptides decrease mitochondrial
ROS generation, inhibit mitochondrial swelling, and reduce
cytochrome c release frommitochondria in different experimental
models (Szeto, 2008). These findings have suggested their
therapeutic potential in neurodegenerative disorders including
AD.
Methylene Blue
Mechanism of Action
Methylene blue (MB) is an FDA-approved drug used for the
treatment of various diseases like malaria and some psychiatric
disorder for more than 100 years (Naylor et al., 1988; de-Oliveira
and Guimarães, 1999; de Oliveira et al., 2000; Oz et al., 2012).
MB possess better pharmacokinetic profile, readily absorbed in
blood and quickly distributed to various organs (Peter et al.,
2000; Rengelshausen et al., 2004). Other functions of MB includes
cognition enhancing properties and increase oxygen consumption
efficacy in isolated mitochondria (Zhang et al., 2006). MB
(1 mg/kg) has also reported to increase COX activity and thereby
improving energy functions in AD brains (Gonzalez-Lima et al.,
1997; Valla et al., 2001; Callaway et al., 2004; Hauptmann et al.,
2009).
Preclinical Studies
It is nowwell known that complex I of ETC is themost susceptible
to oxidative stress in AD (Leuner et al., 2007). A study on mice
showed that MB (0.07 mg/kg) when administered in the eyes
of mice (intravitreally) by the help of microinjector significantly
reverses rotenone induced mitochondrial dysfunction (Complex
I inhibitors; Zhang et al., 2006). Neuroprotective effect of MB
(0.15–4.0 mg/kg b.w, i.p.) has been well demonstrated in animal
models of cognitive dysfunction (Deiana et al., 2009). It has also
been reported that disturbances in the ETC generally elevate
ROS level, which in turn increases Ab production, Ab impairs
mitochondrial function, and hence finally a vicious cycle is
initiated (Leuner et al., 2012). MB (as a redox compound),
prevents the reduction ofmolecular oxygen to superoxide (Leuner
et al., 2007). Thus MB acts as both mitochondrial restorer as well
as antioxidant.
Ginkgo biloba
Mechanism of Action
EGb761® is a standardized extracts of Ginkgo biloba, herbal drug,
used for the improvement of cognitive dysfunction. The extract
consists of 24% flavonoids and 6% terpenes (Bedir et al., 2002;
Sastre et al., 2002; Abdel-Kader et al., 2007).
Preclinical Studies
Study on PC12 cells showed that EGb761® significantly improved
MMP and restored ATP levels after sodium nitroprusside (a
nitric oxide donor) induced mitochondrial damage (Abdel-Kader
et al., 2007). Similar results have been observed in isolated
brain cells and brain mitochondria after treatment with EGb761®
(Eckert et al., 2005). In vitro studies on PC12 cells having
mutant APP, showed that EGb761® (0.01 mg/ml) treatment
leads to enhanced Ab production and increase mitochondrial
functions (Eckert et al., 2005; Abdel-Kader et al., 2007). Animal
study involving EGb761® (100 mg/kg) treatment for 14 days
significantly improved complexes I, IV, and V activities of
the mitochondria and alleviated nitrosative stress (Abdel-Kader
et al., 2007). Further, protective mechanism is due to the
presence of terpene lactones that restoremitochondrial functional
properties and acts as a free radical scavenger (Abdel-Kader
et al., 2007). Recently EGb761® showed an improvement in
neuroplasticity, oxidative stress, long-term potentiation, spine
density, neurogenesis (Müller et al., 2012). Besides, EGb761® alters
APP processing, by upregulating the activity of a-secretase in
hippocampal region (Colciaghi et al., 2004).
Clinical Studies
Clinically Ginkgo biloba has been well studied in dementia due to
mitochondrial restoring properties (Stoll et al., 1996; Tang et al.,
2002; Abdel-Kader et al., 2007;Wang et al., 2010;Weinmann et al.,
2010). However, its neuroprotective mechanism is still not clear.
Curcumin
Mechanism of Action
Also known as diferuloylmethane, yellow pigment derived
from the rhizome part of the turmeric plant (Curcuma longa,
Sikora et al., 2010). It is lipophilic phenolic diferuloylmethane
and possesses varieties of pharmacological functions, including
anti-inflammatory, antioxidative, anti-proliferative, cholesterol-
lowering, and neuroprotective (Bengmark, 2006; Lapchak, 2011;
Vauzour, 2012). Curcumin affects various pathways involved in
AD like neuroprotective processing of APP, tau phosphorylation,
neuroinflammation, or oxidative stress (Zhu et al., 2004).
Preclinical Studies
Apreclinical study on PC12 neuronal cells, showed that curcumin
(25 mmol/l) given for 2 h maintained redox potential and
respiratory functions of mitochondria after hydroxynonenal
(4-HNE) treatment (Raza et al., 2008). Another study on
neurons of rat cortices treated with tert-butyl hydroperoxide
(t-BHP) to induce oxidative stress showed that curcumin
(2.5–20 mmol/l) improves MMP and cytochrome c release,
inhibits the activation of caspase-3, and altered the expression
of Bcl-2 (Zhu et al., 2004). A study on homocystein-induced rat
agingmodel showed that curcumin (5, 15, or 45mg/kg) treatment
significantly decreased MDA and superoxide anion levels and
finally improves learning and memory (Ataie et al., 2010).
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Another study in aged mice showed curcumin’s antioxidative
effects with significant decrease in ROS level and protein
carbonylation (Dkhar and Sharma, 2010). In another in vivo
study, chronic administration of d-galactose causes cognitive
dysfunction, oxidative stress, and impairedmitochondrial enzyme
complex I, II, and III levels and curcumin treatment (15 and
30 mg/kg) for 6 weeks significantly improved cognition, oxidative
stress, and restored mitochondrial enzyme complex activity as
compared to control (Kumar et al., 2011). Curcumin (120 mg/kg)
in a diabetic rat model, up- regulate mitochondrial complex
activities and increase ATP level in the brain (Rastogi et al.,
2008).
Clinical Studies
Curcumin, due to its poor bioavailability and poor water
solubility, may have limited clinical trials (Belkacemi et al., 2011).
So, for effective therapy, new delivery strategies may need to be
developed.
Omega-3 Polyunsaturated Fatty Acids
Mechanism of Action
Omega-3 polyunsaturated fatty acids (&-3 PUFAs) are groups of
essential fatty acids. It functions as energy substrates and is a part
of integral membrane components. Therefore, plays major roles
in the management of neurological function (Cole et al., 2009). A
recent study showed that &-3 PUFAs exerts neuroprotective role
in the cognitive dysfunction (Eckert et al., 2011). Brain fulfills
the need of &-3 PUFAs by the delivery through blood because
of their limited synthesis (Cole et al., 2009). It has been reported
that decreased levels of&-3 PUFAs or fish consumption increases
risk for age-related cognitive deficits such as AD (Cole et al.,
2009).
Preclinical Studies
In vitro studies in HEK-APP cells showed beneficial effects of &-
3 PUFAs (20 mmol/l) as it significantly increased mitochondrial
membrane properties and processing of non-amyloidogenic APP,
which causes enhanced secretion of sAPPa, that in turn protect
against mitochondrial dysfunction and apoptosis (Eckert et al.,
2011). It has also been reported that supplementations with
&-3 PUFAs increase membrane phospholipid docosahexaenoic
acid (DHA). &-3 PUFAs also known to improve the functions
of complexes I and IV of mitochondrial respiratory chain,
mitochondrial respiration and lipid metabolism (Barceló-Coblijn
et al., 2003; Stanley et al., 2012).
Current Trends in Management of Mitochondrial
Related Diseases
Mitochondrial Replacement Therapy
It has been reported that each cell contains almost 1,000 to 100,
000 copies of mtDNA which via maternal inheritance transfers
to the offspring (Swerdlow et al., 2014). Various techniques have
been introduced like genetic screening of embryos, and have
been reported to partially decrease the risk of mitochondrial
diseases transmitted from mother to offspring being (Tachibana
et al., 2009; Reinhardt et al., 2013). Recently a new technique
is introduced, mitochondrial replacement therapy, in which
mitochondria healthy in nature are taken from a donor, is under
investigation. A limitation of this approach is the combination
of the genetic material from three different people, which causes
array of ethical, safety and medical expostulations (McNamee,
2015).
Mitochondrial Editing Technique
It has been reported first time the gene-editing technology, the
technique used to prevent mitochondrial diseases of humans
from being transferred from female their offspring. Researchers
from Salk Institute for Biological Studies in La Jolla, CA, USA
discover mitochondrial editing technique for the treatment of
various neurodegenerative disorders. It is safe, simple and more
ethical as compared to mitochondrial replacement therapy as
it does not involve donor DNA. It is an alternative approach
which involves editing the mutated DNA ofmouse using enzymes
called as restriction endonucleases and transcription activator-
like effector nucleases (TALENs). According to the author of
the Salk Institute for Biological Studies, “this technique is based
on a single injection of mRNA into a mother’s oocytes or
early embryos and therefore could be easily implemented in
IVF (in vitro fertilization) clinics throughout the world.” As
mutation in mitochondrial DNA is involved in a variety of
neurodegenerative disorders, cancer and aging, this technology
may have broader potential therapeutic significance for the
prevention of transmission of disease-causing mutations from
mother to future generations, said by one of the author Belmonte
(McNamee, 2015).
Conclusion
As in neurodegenerative diseases the two pathophysiological
hallmarks mitochondrial dysfunction and oxidative stress were
involved. In AD, apart from theses two other hallmarks are
impaired energy metabolism, excessive ROS generation, impaired
Ca2+ signaling, and increasedmtDNAmutations and disturbance
in OXPHOS. Mitochondrial dysfunction plays critical role in AD
and can be considered as an important target for the treatment
of clinical symptoms of AD. Previous evidences have shown
the potential efficacy of various bioenergetics and antioxidants
having in the treatment of AD, for example coenzyme Q10,
carnitine, a-lipoic acid, Idebenone, mito-targeted compounds
like Mito Q, Mito Vit E and Mito TEMPOL, Ginkgo biloba,
curcumin and omega-3 polyunsaturated fatty acids. Preclinical
data of the above mentioned drugs indicated beneficial effects,
whereas most of the clinical trials did not. This might be because
mitochondrial dysfunction represents an early event in AD
progression and pharmacological interventionsmight came in the
later event in AD. Targeting abnormal mitochondrial dynamics
in AD may represent a novel therapeutic strategy which leads
to the development of new mitochondrial targeted bioenergetics
and antioxidants. Mitochondrial dysfunction and oxidative stress
are also useful in defining the complex pathophysiology of
this disabling disease. Still, more studies are urgently required
to focus on the therapeutic interventions before the disease
progresses.
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